Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome

European Journal of Cancer

Volumn 48, Issue 10, 2012, Pages 1519-1524

  Dabydeen, Donnette A ^a   Jagannathan, Jyothi P ^a   Ramaiya, Nikhil ^a   Krajewski, Katherine ^a   Schutz, Fabio A B ^a   Cho, Daniel C ^b   Pedrosa, Ivan ^b   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Everolimus; Lung toxicity; Mammalian target of rapamycin (mTOR) inhibitors; Renal cell carcinoma; Temsirolimus

Indexed keywords

EVEROLIMUS; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; METASTASIS; PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PNEUMONIA; RETROSPECTIVE STUDIES; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84862002981     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.03.012     Document Type: Article

References (14)

1. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2007 2271 2281
2. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
3. M.B. Atkins, M. Hidalgo, and W.M. Stadler Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 5 2004 909 918
4. J. Bellmunt, C. Szczylik, J. Feingold, A. Strahs, and A. Berkenblit Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features Ann Oncol 19 8 2008 1387 1392
5. I. Duran, L.L. Siu, and A.M. Oza Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus Eur J Cancer 42 12 2006 1875 1880
6. J.P. Maroto, G. Hudes, and J.P. Dutcher Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus J Clin Oncol 29 13 2011 1750 1756
7. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 18 2010 4256 4265
8. D.A. White, P. Camus, and M. Endo Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma Am J Respir Crit Care Med 182 3 2010 396 403
9. E. Morelon, M. Stern, and D. Israel-Biet Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients Transplantation 72 5 2001 787 790
10. T. Weichhart, G. Costantino, and M. Poglitsch The TSC-mTOR signaling pathway regulates the innate inflammatory response Immunity 29 4 2008 565 577
11. F. Schmitz, A. Heit, and S. Dreher Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells Eur J Immunol 38 11 2008 2981 2992
12. B.I. Rini, D.P. Cohen, and D.R. Lu Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 9 2011 763 773
13. R. Perez-Soler, A. Chachoua, and L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 16 2004 3238 3247
14. B. Seruga, H.K. Gan, and J.J. Knox Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer Curr Oncol 16 Suppl. 1 2009 S52 S59